Keyword: Vertex Pharmaceuticals

Vertex Pharma

31. Trikafta

With its five-months-early FDA approval for Trikafta, Vertex ushered in the triple combo era in cystic fibrosis—and majorly expanded its treatable population in the process.

Kymera Therapeutics

Looking to harness the body’s protein degradation processes, Kymera has raised more than $150 million for its pipeline of small molecules, led by a program targeting IRAK4, a protein involved in disease-signaling pathways.